tiprankstipranks
Trending News
More News >
Transcenta Holding Limited (HK:6628)
:6628
Hong Kong Market
Advertisement

Transcenta Holding Limited (6628) AI Stock Analysis

Compare
2 Followers

Top Page

HK:6628

Transcenta Holding Limited

(6628)

Rating:53Neutral
Price Target:
HK$3.00
▲(0.33% Upside)
The stock score is primarily influenced by significant financial challenges, including negative margins and cash flow struggles. Despite positive technical analysis indicating short-term momentum, the negative valuation metrics reflect financial instability. Investors should be cautious, considering the need for financial restructuring and the absence of a dividend yield.

Transcenta Holding Limited (6628) vs. iShares MSCI Hong Kong ETF (EWH)

Transcenta Holding Limited Business Overview & Revenue Model

Company DescriptionTranscenta Holding Limited, a clinical stage biopharmaceutical company, engages in the discovery, research, development, manufacture, and commercialization of various drugs in the People's Republic of China and the United States. The company develops MSB2311, a humanized PD-L1 monoclonal antibody (mAb) candidate for TMB-H solid tumors; TST001, a humanized claudin 18.2 mAb candidate for solid tumors, such as gastric cancer and is under Phase II clinical trial; TST005, a PD-L1/TGF-ß bi-functional antibody candidate which is under Phase Ia clinical trial for solid tumors, including certain lung cancers; TST010, an antibody candidate targeting regulatory T cells to enhance T cell mediated tumor killing;TST002 (Blosozumab), a humanized sclerostin mAb candidate for osteoporosis; and TST004, a humanized mannan-binding lectin serine protease 2 (MASP 2) mAb candidate for IgA kidney diseases. It also develops TST003, an antibody candidate targeting a novel immune regulatory protein produced by tumor-associated fibroblasts or tumor cells with mesenchymal phenotype; TST006, a bi-specific claudin 18.2/PD-L1 antibody; TST008, a tri-functional antibody combining a MASP2 antibody fused with a truncated transmembrane activator and CAML interactor protein; MSB0254, a humanized VEGFR-2 mAb candidate for solid tumors and is under Phase Ib/IIa clinical trials; and MSB2311, A humanized PD-L1 mAb Candidate for solid tumors and is under Phase Ib/IIa clinical trials Transcenta Holding Limited has collaboration agreements with Eli Lilly and Company, Alebund Pharmaceuticals, and Merck. The company was formerly known as MabSpace International Limited and changed its name to Transcenta Holding Limited in June 2019. Transcenta Holding Limited was incorporated in 2010 and is headquartered in Suzhou, the People's Republic of China.
How the Company Makes MoneyTranscenta makes money through the development and commercialization of its biologic drug candidates. The company's revenue model is primarily based on partnerships and collaborations with other pharmaceutical companies, where they may receive milestone payments, royalties, and licensing fees for the rights to develop and market their drug candidates. Additionally, Transcenta invests in manufacturing capabilities to support its pipeline, which can also generate revenue through contract manufacturing services offered to other biotech companies. Significant partnerships with global pharmaceutical firms enhance Transcenta's capabilities in research and development, providing a steady flow of income through strategic collaborations.

Transcenta Holding Limited Financial Statement Overview

Summary
Transcenta Holding Limited faces significant financial challenges with negative profit margins and declining revenues. The balance sheet shows moderate health but high leverage, and cash flow analysis reveals severe distress with negative free cash flows. Overall, financial performance is weak with a need for strategic restructuring.
Income Statement
30
Negative
The income statement reveals significant challenges for Transcenta Holding Limited. The company has experienced a declining revenue trend, with a notable drop from 2022 to 2023. Gross profit margin has decreased significantly, indicating rising costs or pricing pressures. Net profit margins are negative due to substantial net losses, reflecting ongoing financial struggles. Both EBIT and EBITDA margins are deeply negative, underscoring poor operational performance.
Balance Sheet
55
Neutral
The balance sheet shows moderate financial health with some areas of concern. The debt-to-equity ratio is relatively high, indicating significant leverage. However, the equity ratio is positive, suggesting a stable asset base. Return on equity is negative due to net losses. Overall, the balance sheet reflects potential risk from high debt levels but also indicates some strength in asset management.
Cash Flow
25
Negative
Cash flow analysis indicates severe financial distress. The company reports zero or negative free cash flows across recent periods, highlighting a lack of cash generation capability. The operating cash flow to net income ratio is unfavorable, and free cash flow growth rate is negative, illustrating ongoing cash flow challenges.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue11.26M53.85M101.89M50.24M80.98M
Gross Profit4.00M14.40M19.89M9.37M18.20M
EBITDA-233.12M-393.01M-334.09M-1.65B-264.81M
Net Income-290.29M-462.57M-406.75M-1.72B-322.90M
Balance Sheet
Total Assets1.20B1.69B2.13B2.54B2.09B
Cash, Cash Equivalents and Short-Term Investments169.42M546.03M895.45M1.22B813.59M
Total Debt250.61M409.63M411.46M364.71M254.30M
Total Liabilities448.64M665.67M660.64M579.39M2.91B
Stockholders Equity751.64M1.03B1.47B1.97B-816.25M
Cash Flow
Free Cash Flow-216.15M-373.80M-318.03M-457.84M-237.73M
Operating Cash Flow-213.83M-358.04M-295.81M-384.50M-174.40M
Investing Cash Flow14.28M57.47M-102.61M-69.77M-57.74M
Financing Cash Flow-178.06M-47.20M26.72M879.71M620.17M

Transcenta Holding Limited Technical Analysis

Technical Analysis Sentiment
Positive
Last Price2.99
Price Trends
50DMA
2.01
Positive
100DMA
1.69
Positive
200DMA
1.27
Positive
Market Momentum
MACD
0.40
Positive
RSI
56.60
Neutral
STOCH
33.27
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6628, the sentiment is Positive. The current price of 2.99 is above the 20-day moving average (MA) of 2.68, above the 50-day MA of 2.01, and above the 200-day MA of 1.27, indicating a bullish trend. The MACD of 0.40 indicates Positive momentum. The RSI at 56.60 is Neutral, neither overbought nor oversold. The STOCH value of 33.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6628.

Transcenta Holding Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
71
Outperform
HK$1.93B46.624.92%38.48%
57
Neutral
HK$917.05M-266.90%31.23%
53
Neutral
HK$1.37B-32.59%-79.65%37.50%
52
Neutral
HK$3.85B-75.64%42.21%29.52%
51
Neutral
$7.39B0.36-62.86%2.36%15.48%-2.68%
51
Neutral
HK$765.30M
-1.73%-689.53%
36
Underperform
HK$933.41M-41.20%85.23%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:6628
Transcenta Holding Limited
2.99
1.59
113.57%
HK:9939
Kintor Pharmaceutical Ltd
2.09
1.13
117.71%
HK:1875
TOT BIOPHARM International Co. Ltd.
2.41
0.55
29.57%
HK:2197
Clover Biopharmaceuticals Ltd.
0.58
0.30
107.14%
HK:2257
Sirnaomics Ltd.
8.07
3.99
97.79%
HK:3681
SinoMab Bioscience Ltd.
3.06
1.46
91.25%

Transcenta Holding Limited Corporate Events

Transcenta Implements Strategic Measures to Enhance Financial Stability and Pipeline Development
Jul 11, 2025

Transcenta Holding Limited has announced a series of strategic measures to address a disclaimer of opinion in its 2024 annual report, focusing on improving its financial position and liquidity. The company is actively engaging in global partnerships, licensing, and fundraising activities to support its major pipeline assets and other development projects. These efforts include negotiating with banks for credit facilities, collaborating with suppliers for culture media, and exploring technology licensing opportunities. These initiatives are aimed at securing funding and strategic collaborations to advance the company’s innovative therapeutics development and operational stability.

Transcenta Clarifies Option Grant to Consultant Dr. Caroline Germa
Jul 7, 2025

Transcenta Holding Limited announced a clarification and supplemental information regarding the grant of 2,000,000 options to Dr. Caroline Germa under its Share Incentive Scheme. Dr. Germa, a consultant and former executive of the company, plays a crucial role in advising on clinical development and other strategic areas. The option grant aims to incentivize her continued engagement and align her interests with the company’s goals. The vesting of these options is based on performance targets related to clinical and business development milestones, reflecting the company’s strategic objectives.

Transcenta Grants Shares and Options to Key Employees
Jun 25, 2025

Transcenta Holding Limited announced the granting of 90,000 Award Shares and 2,000,000 Options under its Share Incentive Scheme on June 25, 2025. The awards are aimed at incentivizing and retaining key employees, including Dr. Xu, Mr. Tang, and Mr. Zhang, to support the company’s ongoing operations and long-term growth. The shares will vest over three years, with no performance targets attached, reflecting the company’s strategy to reward and retain talent crucial for its development.

Transcenta Holding Limited Announces Successful AGM Outcomes
Jun 6, 2025

Transcenta Holding Limited announced the successful outcomes of its Annual General Meeting held on June 6, 2025, where all proposed resolutions were approved by shareholders. Key resolutions included the re-election of directors, the re-appointment of Deloitte Touche Tohmatsu as auditors, and the authorization for the board to manage share buybacks and issuances. This reflects strong shareholder support and positions the company for continued strategic growth.

Transcenta Unveils Promising Osemitamab Trial Results at ASCO 2025
Jun 2, 2025

Transcenta Holding Limited announced promising new data from its Phase II trial of Osemitamab (TST001) for advanced gastric or gastroesophageal junction cancer, presented at the 2025 ASCO Annual Meeting. The trial results indicate significant survival benefits, with a median overall survival of 20.4 months for all patients and 21.7 months for those with higher CLDN18.2 expression. These findings strengthen the company’s commitment to advancing this treatment, potentially improving patient outcomes and enhancing its position in the oncology market.

Transcenta Holding Limited Schedules 2025 Annual General Meeting
May 13, 2025

Transcenta Holding Limited has announced its upcoming Annual General Meeting to be held on June 6, 2025, in Suzhou, China. The meeting will address several key resolutions, including the adoption of the company’s audited financial statements for 2024, re-election of directors, and re-appointment of Deloitte Touche Tohmatsu as the company’s auditor. Additionally, the meeting will consider granting the board of directors mandates to buy back shares and to issue additional shares, which could impact the company’s market activities and shareholder value.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 05, 2025